

# Analysis of the *Kit* and *Pdgfra* genes in the patch-extended (*Ph<sup>e</sup>*) mutation†

DENNIS A. STEPHENSON<sup>1,2\*</sup>, EDWARD K. NOVAK<sup>2</sup> AND VERNE M. CHAPMAN<sup>2</sup>

<sup>1</sup>The Galton Laboratory, Department of Biology, University College London, 4 Stephenson Way, London NW1 2HE, UK

<sup>2</sup>Department of Molecular and Cellular Biology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263-0001, USA

(Received 20 April 1998 and in revised form 21 May 1998)

## Summary

The patch (*Ph*) locus allele, patch-extended (*Ph<sup>e</sup>*), has significantly less pigmentation than the original mutation and homozygotes have been known to survive to term. Analysing inter-subspecific F1 hybrids, we were able to demonstrate that *Ph<sup>e</sup>* is a deletional mutation encompassing the platelet-derived growth factor receptor alpha subunit (*Pdgfra*). The deletion does not appear to extend into the coding sequence of the *Kit* gene (a related tyrosine kinase receptor). However, we were able to demonstrate that, while the *Kit* gene is transcribed, it does not encode a functionally active receptor.

## 1. Introduction

Mouse spotting mutants have received considerable attention over the past few years following the initial observation of an association between the KIT tyrosine kinase cell surface receptor and the dominant spotting (*W*) locus on chromosome 5 (Chabot *et al.*, 1988; Geissler *et al.*, 1988). Some studies have focused on the identification of the specific molecular defects in the *Kit* gene associated with mutant alleles (Nocka *et al.*, 1989; 1990; Reith *et al.*, 1990; Tan *et al.*, 1990; Duttlinger *et al.*, 1993; Nagle *et al.*, 1995), whereas others have examined the developmental consequence of *Kit* gene expression (Nishikawa *et al.*, 1991; Duttlinger *et al.*, 1993). In addition to this, the ligand for the KIT receptor was shown to be encoded by the steel (*Sl*) locus (Copeland *et al.*, 1990; Flanagan & Leder, 1990; Huang *et al.*, 1990; Williams *et al.*, 1990; Zsebo *et al.*, 1990), providing a direct link between

these phenotypically similar but genetically distinct loci.

Closely associated with the *Kit* gene, on chromosome 5, is the patch (*Ph*) locus (Grüneberg & Truslove, 1960), which was shown to be a deletional mutation encompassing the platelet-derived growth factor receptor alpha subunit (*Pdgfra*) by Smith *et al.* (1991) and Stephenson *et al.* (1991). While the *Kit* gene appears to be intact (Stephenson *et al.*, 1991) subsequent investigations have indicated that *Kit* expression is disrupted in the *Ph* mutant (Duttlinger *et al.*, 1995; Wehrle-Haller *et al.*, 1996). It is the disruption of *Kit* gene expression that may account for the spotting phenotype associated with the *Ph* mutation. This is substantiated, in part, by the genomic rearrangement alleles at the *Kit* locus itself (Duttlinger *et al.*, 1993; Nagle *et al.*, 1994, 1995; Klupple *et al.*, 1997) and the genetically engineered ‘knock-out’ mutant of the *Pdgfra* gene (Soriano, 1997). While the knock-out homozygotes exhibit some of the characteristics of *Ph* homozygotes, knock-out heterozygotes do not have the spotting phenotype of the *Ph* heterozygotes.

The *Ph* locus is characterized by two alleles: the original mutant *Ph* (Grüneberg & Truslove, 1960) and patch-extended, *Ph<sup>e</sup>* (Truslove, 1977). Both mutations are semi-dominant; the *Ph* heterozygote has a variable-sized mid-ventral white spot (Fig. 1A), whereas the *Ph<sup>e</sup>* heterozygote has a more extensive spotting phenotype encompassing most of the body

\* Corresponding author. The Galton Laboratory, Department of Biology, University College London, 4 Stephenson Way, London NW1 2HE, UK. Telephone: +44(171)380 7423. Fax: +44(171)383 2048. e-mail: das@galton.ucl.ac.uk.

† Dedicated to Bruce Cattanaach on the occasion of his retirement as director of the MRC Mammalian Genetics Unit. Bruce, as Jean-Louis Guénet put it, was part of a unique group of scientists at Harwell, who not only made a substantial contribution to our understanding of genetics, but was more than willing to share resources with the community at large. Like Verne, Bruce was known to have just the right mutant mouse to answer the burning genetic issues. A true gentleman and friend.




Fig. 1. Pigmentation phenotype of  $Ph/+$  heterozygote (A);  $Ph+/+Kit^W$  compound heterozygote (B);  $Ph^e/+$  heterozygote (C); and  $Ph^e+/+Kit^W$  compound heterozygote (D). Both the  $Ph^e/+$  heterozygote and  $Ph+/+Kit^W$  compound heterozygote have a similar but significantly enhanced white spotting phenotype compared with that observed in the  $Ph/+$  heterozygote. However, the  $Ph^e+/+Kit^W$  compound heterozygote has the black-eyed white coat phenotype characteristic of that produced in complementation involving different *Kit* alleles.

(Fig. 1 C). While most homozygotes for both alleles usually die around mid-gestation with gross anatomical abnormalities, one presumptive  $Ph^e$  homozygote with a split face did survive to term. Although complementation studies suggested allelism with the *Ph* locus, the phenotype of the  $Ph^e+/+Kit^W$  compound heterozygote (Fig. 1 D) would also suggest allelism with *Kit* as well. Given this situation we decided to ascertain the molecular defect associated with the  $Ph^e$  allele.

## 2. Methods

### (i) Mice

The patch-extended mutation was obtained from Dr Gillian Truslove at University College, London. The dominant spotting mutation was purchased from the Jackson Laboratory, Maine. The wild-derived *Mus musculus* PWK stock was originally established from animals trapped in Czechoslovakia and has been maintained as an inbred line at Roswell Park for more than 20 generations of sib matings.

### (ii) Crosses

Inter-subspecific F1 hybrids were produced by crossing a patch-extended heterozygous female to a PWK

male. Patch-extended dominant spotting ( $Ph^e+/+Kit^W$ ) compound heterozygotes were obtained from crosses between the patch-extended mutant stock and the dominant spotting mutant stock and identified on the basis of their characteristics (i.e. black-eyed white coat phenotype). Dominant spotting homozygotes ( $Kit^W/Kit^W$ ) were obtained by crossing heterozygotes together and collecting fetuses 16 days *post-coitum*. They were also identified on the basis of phenotype (i.e. an anaemic-looking liver).

### (iii) DNA extraction and purification

High-molecular-weight genomic DNA was prepared from either fresh or frozen kidneys using standard extraction techniques described previously (Mullins *et al.*, 1988).

### (iv) RNA extraction and purification

Fresh brain tissue was homogenized in a solution containing 4 M guanidine thiocyanate, 20 mM sodium acetate, 0.1 mM dithiothreitol (DTT) and 0.5% *N*-lauryl sarcosine. The RNA was collected as a pellet after ultracentrifugation on a caesium chloride gradient. After resuspension, the RNA was further purified by ethanol precipitation.

(v) *Southern blot analysis*

Approximately 5 µg of DNA was digested with either *Bgl*II or *Pst*I restriction endonuclease in accordance with the manufacturer's recommendations (either Bethesda Research Laboratories, Promega or Stratagene). The digested DNA was resolved on an 0.8% agarose gel (SeaKem, FMC) in TAE buffer (40 mM Tris-acetate and 2 mM EDTA, pH 7.5). After denaturation, the DNA was transferred to Zetabind membrane (AMF, Cuno) using the Southern blot technique (Southern, 1975). Blots were hybridized with either *Kit* or *Pdgfra* using previously defined conditions (Stephenson *et al.*, 1991).

(vi) *Northern blot analysis*

Approximately 5 µg of total RNA was resolved on a 1.2% agarose gel containing 1% formaldehyde with MOPS running buffer (200 mM 3[*N*-morpholino]-propane sulphonic acid, 50 mM sodium acetate, 10 mM EDTA, pH 7). The RNA was blotted onto Zetabind membrane and hybridized overnight at 50 °C with a radioactively labelled cDNA probe to the *Kit* gene in a solution containing 5% SDS, 0.5 M phosphate buffer pH 7.4. The blot was washed several times in 4 × SSC 0.1% SDS at 50 °C then exposed to X-ray film at –70 °C. The film was developed 12 h later.

(vii) *RT-PCR*

RNA from the compound heterozygote together with suitable controls was reverse transcribed using the Moloney murine leukaemia virus (M-MuLV) reverse transcriptase (New England BioLabs) from an oligo-dT primer. The conditions used were those recommended by the manufacturer. An aliquot of the reversed transcribed reaction mix was subsequently used in two separate PCR reactions. The first involved amplification of a fragment spanning the transmembrane domain from the forward (KIT1550: CAAGAGTTCGCTTCTTTA) and reverse (KIT1851: ATCCGACTTAATCAAGCCAT) primers. The second involved the amplification of the cytoplasmic domain from a forward (KIT1649: GATGGGGATCATTGTGATGG) primer within the transmembrane domain and a reverse (KIT3000: ATCACAGAAGCCAGAAGGACG) primer at the C-terminal end. The same conditions were used for both reactions: buffer supplied by the manufacturer was used with the *Taq* polymerase (Boehringer–Mannheim, Indianapolis, IN) supplemented with 4 mM MgCl<sub>2</sub> and 25 µM dinucleotide triphosphates (dNTPs). Amplification was performed on an MJ thermocycler machine (MJ Research, Watertown, MA) according to the following protocol: one cycle of

94 °C for 4 min, 55 °C for 1 min, 72 °C for 5 min; 35 cycles of 94 °C for 1 min, 55 °C for 1 min, 72 °C for 2 min; and a final cycle of 94 °C for 4 min, 55 °C for 1 min, 72 °C for 5 min. The amplification product was examined on a 1% agarose gel.

(viii) *KIT immunoprecipitation and in vitro kinase assay*

Antibody raised against the KIT receptor was the gift of Dr Alan Bernstein, Mount Sinai Research Institute, Toronto. Brain tissue was homogenized in RIPA buffer and processed according to Reith *et al.* (1990). Briefly, 500 µl of brain lysate, cleared by centrifugation, was mixed with 5 µl pre-immune serum plus 50 µl of 10% protein A sepharose and incubated for 2 h at 4 °C. After centrifugation, the supernatant was mixed with 5 µl rabbit anti-KIT plus 50 µl of 10% protein A sepharose and incubated for a further 2 h at 4 °C. The immunoprecipitate–protein A sepharose complex was washed three times with RIPA buffer and two times with 50 mM Tris-HCl (pH 7.5) and 1% Triton X-100. The immune complex was resuspended in 10 µl of kinase reaction buffer containing 10 mM MnCl<sub>2</sub>, 1% Triton X-100 and 10 µCi [ $\gamma$ -<sup>32</sup>P]ATP. The kinase reaction was incubated at 30 °C for 10 min then mixed with an equal volume of loading buffer. After electrophoresis on 7% SDS-acrylamide gel, the gel was fixed in 10% acetic acid, 30% methanol, followed by treatment with 1 M KOH prior to autoradiography as described by Reith *et al.* (1990).

**3. Results**

Genomic DNA from inter-subspecific F1 hybrids between the *Ph<sup>e</sup>* mutant and the wild-derived *Mus musculus* PWK strain was digested with *Pst*I and hybridized with a full-length cDNA clone to the mouse *Pdgfra* gene. Previous studies (Stephenson *et al.*, 1991) had established that this restriction endonuclease identified a useful polymorphism in the two alleles of the *Pdgfra* gene. The results of this analysis are present in Fig. 2. F1 hybrids carrying the *Ph<sup>e</sup>* allele lacked some of the fragments detected in their wild-type sibs (i.e. 5.2, 4.9, 3.5, 2.6, 2.0 kb). These fragments are diagnostic of the laboratory allele for the *Pdgfra* gene. However, fragments defining the PWK allele (i.e. 7.9, 4.8, 2.8, 2.5 kb) were present. These results demonstrate that *Ph<sup>e</sup>*, like *Ph* itself (Stephenson *et al.*, 1991; Smith *et al.*, 1991), carries a deletion of the *Pdgfra* gene.

Analysis of the *Kit* gene, also using a previously defined polymorphism (Stephenson *et al.*, 1991), failed to reveal any abnormalities (data not shown). This would indicate that the *Ph<sup>e</sup>* deletion, like *Ph*




Fig. 2. Southern blot analysis of genomic DNA from inter-specific F1 hybrids between the  $Ph^e$  mutant stock (L) and the wild-derived *Mus musculus* PWK stock (P) with a cDNA clone to the *Pdgfra* gene. The wild-type sibs exhibit a banding pattern that combines the pattern of both parents, whereas the  $Ph^e$  sibs have a banding pattern highly indicative of the PWK parent only (i.e. they lack the unique fragments of the  $Ph^e$  parent).

(Stephenson *et al.*, 1991), does not appear to remove coding sequences associated with the *Kit* gene as defined by the cDNA probe.

We had hoped to establish whether the *Kit* gene encoded by the  $Ph^e$  deletion mutation was functionally transcribed using simple Northern blot analysis, by exploiting a slight difference in size between mRNA encoded by the wild-type and the dominant spotting ( $Kit^W$ ) alleles (Nocka *et al.*, 1990). Brain RNA from a patch-extended/dominant spotting compound heterozygote (i.e.  $Ph^e + / + Kit^W$ ) failed to produce the dual hybridization signal anticipated for this sample (data not shown). However, RT-PCR analysis did provide evidence indicating that the *Kit* gene was transcriptionally active from the deletional chromosome identified by the  $Ph^e$  mutation. A 340 bp product, identifying a normal transmembrane domain, was detected in the sample from the compound heterozygote (Fig. 3a, track B) but not in a sample from the  $Kit^W/Kit^W$  fetus (Fig. 3a, track C) with the primers KIT1550 and KIT1851. Amplification of contaminating genomic DNA can be precluded because the primers would encompass a region containing two or more introns (Andre *et al.*, 1997). As a consequence, the transmembrane fragment would be more than twice the size of that detected off the




Fig. 3. (a) RT-PCR analysis of *Kit* mRNA extracted from the brain of a  $Ph + / + Kit^W$  compound heterozygote (track A),  $Ph^e + / + Kit^W$  compound heterozygote (track B) and  $Kit^W/Kit^W$  homozygote (track C) amplified with KIT1550/KIT1851. (b) Tracks B, C and D respectively correspond to A, B and C in (a), but amplified with KIT1649/KIT3000. Track A in (b) is a *Kit* cDNA control. As *Kit* mRNA encoded by the  $Kit^W$  allele lacks the exon containing the transmembrane domain (Nocka *et al.*, 1990), the presence of a 340 bp (a) and a 1.3 kb product (b) associated with RNA extracted from both compound heterozygotes implies that the *Kit* gene associated with both  $Ph$  alleles is transcribed.

mRNA. Thus, the presence of a 340 bp product is consistent with an mRNA species containing the full-length transmembrane domain. This result was confirmed by the detection of a 1.3 kb (Fig. 3b, track C) product generated by the use of the transmembrane oligo (KIT1649) and an oligo-nucleotide primer from the 3' end of the open reading frame (KIT3000). Amplification of contaminating genomic DNA would have a dramatic impact on the size of the fragment as this region contains 11 introns (Andre *et al.*, 1997), which, if amplified, would add a further 10 kb to the product size. A similar-sized product was not detected in the  $Kit^W/Kit^W$  fetal control (Fig. 3b, track D).

The results of the autophosphorylation analysis are presented in Fig. 4. Autophosphorylation signal at approximately 121 kDa is highly consistent with that associated with the KIT receptor (Nocka *et al.*, 1990). This signal is present in samples taken from the  $Ph$ ,  $Ph^e$  and  $Ph + / + Kit^W$  compound heterozygotes as well as the  $Kit^W$  heterozygote. However, no signal was detected in the  $Ph^e + / + Kit^W$  compound heterozygote.




Fig. 4. Autophosphorylation analysis of immunoprecipitate of KIT protein extracted from the brain of a *Ph*<sup>+</sup>/+ heterozygote (track A), *Ph*<sup>+</sup>/+ *Kit*<sup>W</sup> compound heterozygote (track B), *Ph*<sup>e</sup>/+ heterozygote (track C), *Ph*<sup>e</sup>/+ *Kit*<sup>W</sup> compound heterozygote (track D) and *Kit*<sup>W</sup>/+ heterozygote (track E). The presence of autophosphorylation signal at approximately 121 kDa in every sample except for the *Ph*<sup>e</sup>/+ *Kit*<sup>W</sup> compound heterozygote (track D) suggests that there is a functionally active KIT protein in each sample. The lack of signal in the *Ph*<sup>e</sup>/+ *Kit*<sup>W</sup> compound heterozygote (track D) implies that there is no functionally active KIT protein in this sample.

Similarly, no signal was detected in the *Kit*<sup>W</sup>/*Kit*<sup>W</sup> fetal control (not shown). Previous studies (Nocka *et al.*, 1990) have demonstrated that the KIT receptor encoded by *Kit*<sup>W</sup> is not retained by the cell because it lacks the transmembrane domain; the presence of autophosphorylation in the *Ph*<sup>+</sup>/+ *Kit*<sup>W</sup> compound heterozygote would imply that the *Kit* gene associated with the *Ph* mutation is functionally active. The absence of signal in the *Ph*<sup>e</sup>/+ *Kit*<sup>W</sup> compound heterozygote would imply that the *Kit* gene associated with the *Ph*<sup>e</sup> mutation is functionally inactive. Quantitative measurements of the autophosphorylation signal are reasonably consistent with the level of a functionally active receptor (unpublished observation). Taken together, these observations establish that, while the *Kit* gene from the *Ph*<sup>e</sup> chromosome is transcribed, it does not give rise to a functionally active receptor.

#### 4. Discussion

In the present study we have established that the *Ph*<sup>e</sup> allele at the *Ph* locus is a deletional mutation encompassing the *Pdgfra* gene but not the *Kit* gene. In this respect, it is similar to the *Ph* allele (Stephenson *et al.*, 1991). While there is transcriptional activity from the *Kit* gene encoded by the deletional chromosome of the *Ph*<sup>e</sup> allele, the translational product is not functionally active. This is in contrast to the *Kit* gene encoded on the deletional chromosome associated with the *Ph* allele.

When describing the origins of the *Ph*<sup>e</sup> allele, Truslove (1977) indicated that it arose from a promiscuous mating between a *Ph*/+ female and a *Ph*/+ or *Kit*<sup>Wv</sup>/+ male. The phenotypic similarities between *Ph*<sup>e</sup> heterozygotes and the *Ph*<sup>+</sup>/+ *Kit*<sup>W</sup> compound heterozygote, as well as the observation that *Ph*<sup>e</sup> does not complement mutations at the *Kit* locus, would tend to suggest that the *Ph*<sup>e</sup> mutation also carries a defect in the *Kit* gene. The results of the present study confirm this by demonstrating that, although present, the *Kit* gene associated with the *Ph*<sup>e</sup> is functionally inactive. Abolition of functional kinase activity is a characteristic of several *Kit* alleles including *Kit*<sup>Wv</sup> (Nocka *et al.*, 1990). In conjunction with this and the observation that the *Ph*<sup>e</sup>/+ *Kit*<sup>W</sup> compound heterozygote is slightly anaemic and sterile (Truslove, 1977), it would suggest that the illegitimate mating probably involved the *Kit*<sup>Wv</sup>/+ male. If this were the case, these two alleles, which were in repulsion in the original cross, should have segregated in subsequent matings. As they did not, it would imply that the *Kit* gene associated with the original *Ph* mutant acquired a mutation abolishing its activity. Several mechanisms suggest themselves as possible explanation for this event: (i) a spontaneous mutational event; (ii) a gene conversion event; or (iii) an intergenic recombinational event. While it is probably almost impossible to distinguish between these possibilities, they are not without precedence in nature (see review by Pittman & Schimenti, 1998).

We are grateful to Darla Miller and Arlene Morrow for technical assistance; Debbie Swiatek and Diane Poslinski for help with the animals; and David Whitehouse for his comments on the manuscript. This work was supported by NIH grants GM33160 and HG00170 to V.M.C. and RO1 HL3 1698-13 to R. T. Swank (E.K.N.), and a Nuffield Foundation grant to D.A.S.

#### References

- Andre, C., Hampe, A., Lachaume, P., Martin, E., Wang, X.-P., Manus, V., Hu, W.-X. & Gailibert, F. (1997). Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes. *Genomics* **39**, 216–226.
- Chabot, B., Stephenson, D. A., Chapman, V. M., Besmer, P. & Bernstein, A. (1988). Localization of the *c-kit* proto-oncogene at or near the mouse *W* gene locus. *Nature* **335**, 88–89.
- Copeland, N. G., Gilbert, D. J., Cho, B. C., Donovan, P. J., Jenkins, N. A., Cosman, D., Anderson, D., Lyman, S. D. & Williams, D. E. (1990). Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. *Cell* **63**, 175–188.
- Duttlinger, R., Manova, K., Chu, T. Y., Gyssler, C., Zelenetz, A. D., Bachvarova, R. F. & Besmer, P. (1993). *W*-sash affects positive and negative elements controlling *c-kit* expression: ectopic *c-kit* expression at sites of *kit*-ligand expression affects melanogenesis. *Development* **118**, 705–717.

- Duttlinger, R., Manova, K., Berrozpe, G., Chu, T.-Y., DeLeon, V., Timokhina, I., Chaganti, R. S. K., Zelenetz, A. D., Bachvarova, R. F. & Besmer, P. (1995). The *W<sup>sh</sup>* and *Ph* mutations affect the *c-kit* expression profile: *c-kit* misexpression in embryogenesis impairs melanogenesis in *W<sup>sh</sup>* and *Ph* mutant mice. *Proceedings of the National Academy of Sciences of the USA* **92**, 3754–3758.
- Flanagan, J. G. & Leder, P. (1990). The Kit ligand: a cell surface molecule altered in steel mutant fibroblasts. *Cell* **63**, 185–194.
- Geissler, E., Ryan, M. A. & Houseman, D. E. (1988). The dominant white spotting (*W*) locus of the mouse encodes the *c-kit* proto-oncogene. *Cell* **55**, 185–192.
- Grüneberg, H. & Truslove, G. M. (1960). Two closely linked genes in the mouse. *Genetical Research* **1**, 69–90.
- Huang, E., Nocka, K., Beier, D. R., Chu, T.-Y., Buck, J., Lahm, H.-W., Wellner, D., Leder, P. & Besmer, P. (1990). The hematopoietic growth factor KL is encoded at the *Sl* locus and is the ligand of the *c-kit* receptor, the gene product of the *W* locus. *Cell* **63**, 225–233.
- Kluppel, N., Nagle, D. L., Bućan, M. & Bernstein, A. (1997). Long-range genomic rearrangements upstream of *Kit* disregulate the development pattern of *Kit* expression in *W<sup>57</sup>* and *W<sup>banded</sup>* mice and interfere with distinct steps in melanocyte development. *Development* **124**, 65–77.
- Mullins, L. J., Grant, S. G., Stephenson, D. A. & Chapman, V. M. (1988). Multilocus molecular mapping of the mouse X-chromosome. *Genomics* **3**, 187–194.
- Nagle, D. L., Martin-DeLeon, P., Hough, R. B. & Bućan, M. (1994). Structural analysis of chromosomal rearrangements associated with the developmental mutations *Ph*, *W<sup>19H</sup>* and *Rw* on mouse chromosome 5. *Proceedings of the National Academy of Sciences of the USA* **91**, 7237–7241.
- Nagle, D. L., Kozak, C. A., Mano, H., Chapman, V. M. & Bućan, M. (1995). Physical mapping of the *Tec* and *Gabrb1* loci reveals that the *W<sup>sh</sup>* mutation on mouse chromosome 5 is associated with an inversion. *Human Molecular Genetics* **4**, 2073–2079.
- Nishikawa, S., Kusakabe, M., Yoshinaga, K., Ogawa, M., Hayashi, S., Kunisada, T., Era, T., Sakakura, T. & Nishikawa, S. (1991). *In utero* manipulation of coat color formation by a monoclonal anti-*c-kit* antibody: two distinct waves of *c-kit*-dependency during melanocyte development. *EMBO Journal* **10**, 2111–2118.
- Nocka, K., Majumder, S., Chabot, B., Ray, P., Cervone, M., Bernstein, A. & Besmer, P. (1989). Expression of *c-kit* gene products in known cellular targets of *W* mutations in normal and *W* mutant mice: evidence for an impaired *c-kit* kinase in mutant mice. *Genes and Development* **3**, 816–826.
- Nocka, K., Tan, J. C., Chiu, E., Chu, T. Y., Ray, P., Traktman, P. & Besmer, P. (1990). Molecular bases of dominant negative and loss of function mutations at the murine *c-kit*/white spotting locus: *W<sup>37</sup>*, *W<sup>v</sup>*, *W<sup>41</sup>* and *W*. *EMBO Journal* **9**, 1805–1990.
- Pittman, D. L. & Schimenti, J. C. (1998). Recombination in the mammalian germ line. *Current Topics in Developmental Biology* **37**, 1–35.
- Reith, A. D., Rottapel, R., Giddens, E., Brady, C., Forrester, L. & Bernstein, A. (1990). *W* mutant mice with mild or severe developmental defects contain distinct point mutations in the kinase domain of the *c-kit* receptor. *Genes and Development* **4**, 390–400.
- Smith, E. A., Seldin, M. F., Martinez, L., Watson, M. L., Choudhary, G. G., Lalley, P. A., Pierce, J., Asronson, S., Barker, J., Naylor, S. L. & Sakaguchi, A. Y. (1991). Mouse platelet-derived growth factor receptor alpha gene is deleted in *W<sup>19H</sup>* and patch mutations on chromosome 5. *Proceedings of the National Academy of Sciences of the USA* **88**, 4811–4815.
- Soriano, P. (1997). The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. *Development* **124**, 2691–2700.
- Southern, E. M. (1975). Detection of specific sequences among DNA fragments separated by gel electrophoresis. *Journal of Molecular Biology* **98**, 503–517.
- Stephenson, D. A., Mercola, M., Anderson, E., Wang, C., Stiles, C. D., Bowen-Pope, D. F. & Chapman, V. M. (1991). Platelet-derived growth factor receptor  $\alpha$ -subunit gene (*Pdgfra*) is deleted in the mouse patch (*Ph*) mutation. *Proceedings of the National Academy of Sciences of the USA* **88**, 6–10.
- Tan, J. C., Nocka, K., Ray, P., Traktman, P. & Besmer, P. (1990). The dominant *W<sup>32</sup>* spotting phenotype results from a missense mutation in the *c-kit* receptor kinase. *Science* **247**, 209–247.
- Truslove, G. M. (1977). A new allele at the patch locus in the mouse. *Genetical Research* **29**, 183–186.
- Wehrle-Haller, B., Morrison-Graham, K. & Weston, J. A. (1996). Ectopic *c-kit* expression affects the fate of melanocyte precursors in Patch mutant embryos. *Developmental Biology* **177**, 463–474.
- Williams, D. E., Eisenman, J., Baird, A., Rauch, C., Van Ness, K., March, C. J., Park, L. S., Martin, U., Mochizuki, D. Y., Boswell, H. S., Burgess, G. S., Cosman, D. & Lyman, S. D. (1990). Identification of a ligand for the *c-kit* proto-oncogene. *Cell* **63**, 167–174.
- Zsebo, K. M., Williams, D. A., Geissler, E. N., Broudy, V. C., Martin, F. H., Atkins, H. L., Hsu, R.-Y., Birkett, N. C., Okino, K. H., Murdock, D. C., Jacobsen, F. W., Langley, K. E., Smith, K. A., Takeishi, T., Cattanch, B. M., Galli, S. J. & Suggs, S. V. (1990). Stem cell factor is encoded at the *Sl* locus of the mouse and is the ligand for the *c-kit* tyrosine kinase receptor. *Cell* **63**, 213–224.